5-MeO-DMT-Assisted Therapy
An exceptionally fast-acting psychedelic compound, now moving into late-stage international clinical development.
What is it?
01What is 5-MeO-DMT?
5-MeO-DMT, or 5-methoxy-N,N-dimethyltryptamine, is an exceptionally fast-acting psychedelic compound found naturally in several plants and in the defensive secretions of the Sonoran Desert toad, also known as the Colorado River toad (Incilius alvarius).
It is chemically related to DMT, but the experience can be remarkably different.
5-MeO-DMT is generally associated with more ego dissolution, loss of the ordinary sense of self, feelings of unity and powerful emotional or mystical experiences. Some people describe an experience of becoming completely connected to everything; others experience an intense release of grief, fear, pain or emotion.
It has sometimes been called "the God molecule" because of the extraordinary transcendent or non-dual states people report. This is a cultural nickname rather than a scientific term, but it captures something distinctive about the experience: unlike many psychedelics that produce elaborate visual journeys, 5-MeO-DMT can feel more like the ordinary boundaries between yourself and everything else temporarily disappear.
Its other defining characteristic is its speed.
When inhaled, the psychedelic experience can begin within seconds, peak within minutes and commonly last around 15–20 minutes, with people often returning relatively quickly towards ordinary awareness.
That short duration may eventually become one of its greatest advantages in psychedelic-assisted therapy as it could reduce the costs involved in therapy.
From the toad to the laboratory
5-MeO-DMT occurs naturally in several plant species, but its best-known natural source is the secretion of the Sonoran Desert toad, historically known as Bufo alvarius and now classified as Incilius alvarius. Ceremonial experiences using the dried and vaporised secretion are commonly referred to as "Bufo" ceremonies.
The toad produces a defensive secretion from glands behind its eyes. Although it is often described as "toad venom", toad secretion is the more accurate term. This secretion contains 5-MeO-DMT alongside other naturally occurring compounds.
As global interest in Bufo grew, so did concerns about the repeated handling and harvesting of wild toads. Importantly, 5-MeO-DMT can now be produced synthetically, creating the same active molecule while removing the need to use the animal at all.
Synthetic 5-MeO-DMT also allows researchers to work with a precise, consistent compound and controlled dosing, which is one of the reasons pharmaceutical research is increasingly focusing on synthetic formulations rather than toad-derived material. Researchers have specifically advocated for this transition for ecological, ethical and clinical reasons.
This shift may ultimately allow the therapeutic potential of 5-MeO-DMT to be explored while protecting the animal that first brought the molecule into wider public awareness.
From natural medicine to synthetic therapy
The evolution of 5-MeO-DMT represents something we are seeing repeatedly across psychedelic medicine. A molecule first known through nature is moving into pharmaceutical science.
Synthetic production allows researchers to know precisely what compound is being administered, how much is being delivered and how consistently it behaves, while also removing the need to harvest secretions from wild animals.
This may ultimately be the most ethical and scalable future for 5-MeO-DMT.
Not because its natural history should be forgotten, but because science can honour the molecule without needing to exploit the animal that helped bring it to modern attention.
What may it help with?
025-MeO-DMT is being studied most closely for treatment-resistant depression. Earlier research has also explored anxiety, emotional wellbeing and addiction. You'll find what the research shows so far under What does the evidence say?
How does it work?
03What happens in the brain?
5-MeO-DMT primarily interacts with the brain's serotonin system, particularly the 5-HT1A and 5-HT2A receptors.
This differentiates it somewhat from classic psychedelics such as psilocybin and LSD, which have especially strong effects through 5-HT2A.
5-MeO-DMT appears to produce extraordinarily rapid changes in conscious experience, emotional intensity and the boundaries between the sense of self and the external world.
Researchers are also interested in its possible effects on neuroplasticity, neuroendocrine activity, immune regulation and inflammatory processes, although much of this science remains early. What is particularly interesting therapeutically is the phenomenon known as ego dissolution.
For a short period, the internal narrative of who I am, what has happened to me, what I believe about myself and what I need to protect can radically soften or disappear.
That may create an opportunity to experience yourself and your history from somewhere entirely different.
Why doesn't everyone experience visuals?
One misconception about psychedelics is that a powerful experience must involve elaborate visuals.
5-MeO-DMT is one of the clearest examples of why this is not true.
Research consistently describes it as producing fewer visual phenomena than many other classic psychedelics, while simultaneously producing some of the most powerful reports of ego dissolution, unity and mystical experience.
Some people experience imagery. Others experience almost none. The experience may instead be physical, emotional, existential or almost impossible to describe.
Intensity does not necessarily equal visual intensity.
Dosing and the therapeutic window
5-MeO-DMT is an interesting example of why dose matters enormously in psychedelic medicine.
The difference between a gentler experience and profound ego dissolution can be considerable, and individual responses vary.
Clinical researchers are therefore investigating individualised dose escalation and dose-finding approaches rather than assuming that one dose will be appropriate for everybody. A major pharmacology review specifically highlighted personalised dose escalation as a potentially useful clinical approach with 5-MeO-DMT.
This may ultimately allow clinicians to find the experience that best supports the individual rather than simply pursuing the most intense possible state.
Sometimes going deeper may be valuable. Sometimes being able to remain connected enough to lean into what is emerging may be equally important.
What does the evidence say?
04Treatment-resistant depression
This is currently the most advanced area of clinical development.
In Phase 2 research, a single administration of BPL-003 has produced rapid reductions in depression symptoms in people with treatment-resistant depression.
Early results have reported antidepressant effects beginning quickly and continuing for weeks, with one small open-label study of 12 people reporting benefits lasting as long as three months after a single treatment.
A larger Phase 2b study, reported by the developer, subsequently found statistically significant and clinically meaningful reductions in depressive symptoms following a single treatment, with effects maintained through the eight-week study period. Most participants were considered ready for discharge around 90 minutes after dosing.
BPL-003 has now moved towards Phase 3 development. That makes 5-MeO-DMT considerably more than an experimental fringe psychedelic. It is becoming a serious late-stage psychiatric drug candidate.
Anxiety and emotional wellbeing
Earlier observational research has also reported reductions in self-reported depression, anxiety and stress following 5-MeO-DMT experiences.
A large survey of 515 people who had used 5-MeO-DMT found that among respondents with existing mental-health diagnoses, 77% of those reporting depression, 79% with PTSD and 69% with anxiety reported improvements in symptoms following use.
These were self-reported observational findings rather than controlled clinical trials, so they cannot establish treatment efficacy, but they played an important role in stimulating modern clinical research.
Addiction
Another fascinating emerging area is addiction.
In 2025, researchers published the first Phase 2 proof-of-concept clinical trial examining synthetic 5-MeO-DMT alongside cognitive behavioural therapy for alcohol-use disorder.
Among the 12 participants completing the study, average abstinent days increased substantially over 12 weeks, while heavy drinking days declined. Half of participants remained continuously abstinent during the follow-up period.
The study was small and open-label, so larger controlled trials are needed.
Nevertheless, it presents a particularly interesting possibility: rather than evidence suggesting 5-MeO-DMT inherently drives addiction, researchers are now studying whether it could actually help people change addictive behaviour.
Why is 5-MeO-DMT attracting so much attention?
One of the biggest practical challenges facing psychedelic-assisted therapy is time.
A psilocybin treatment may require six or more hours of clinical supervision. MDMA sessions can extend for six to eight hours, and LSD can continue for eight to twelve hours. That can make these therapies expensive and difficult to scale.
5-MeO-DMT potentially changes that equation.
Its intense psychedelic effects can occur within a window of around 15–30 minutes, and some clinical formulations are being designed so that patients may be ready to leave the clinic within approximately two hours.
This means a treatment that produces a profound altered state may eventually fit into something closer to the infrastructure already used for treatments such as ketamine or esketamine. That could significantly change accessibility.
Researchers are also experimenting with different formulations, routes of administration and duration of effect, essentially asking whether the therapeutic window can be shaped or extended while retaining 5-MeO-DMT's practical advantages.
The US$3.8 billion signal
One of the clearest indications of how seriously pharmaceutical science is beginning to take 5-MeO-DMT arrived in July 2026.
Eli Lilly, one of the world's largest pharmaceutical companies, announced an agreement to acquire psychedelic biotechnology company AtaiBeckley.
The deal is worth approximately US$2.8 billion upfront, with a further US$1 billion linked to development and regulatory milestones, up to US$3.8 billion in total.
AtaiBeckley's leading drug is BPL-003, a synthetic 5-MeO-DMT formulation delivered intranasally and being developed for treatment-resistant depression.
BPL-003 has received Breakthrough Therapy Designation from the US FDA and is now moving into Phase 3 development.
The acquisition does not prove that 5-MeO-DMT will become an approved treatment, and Lilly is acquiring a broader pipeline rather than one molecule alone.
But a pharmaceutical company committing billions of dollars to a business whose lead therapy is synthetic 5-MeO-DMT is an extraordinary indicator of where the science and investment behind the science is heading.
Why the short duration could change psychedelic therapy
The economics of psychedelic therapy matter.
If every therapeutic psychedelic requires six to twelve hours of one-to-one clinical supervision, access will inevitably remain limited and expensive.
Researchers have explicitly identified 5-MeO-DMT's short duration as one of its major potential clinical advantages.
A medicine capable of producing profound psychological effects within minutes could allow treatment programs to operate very differently from longer psychedelic sessions.
The interesting question is whether therapeutic depth requires duration. Early research suggests it may not.
A very short experience may still create psychological changes that continue unfolding long after the acute effects have finished.
What does a session or practice look like?
05What might an experience feel like?
5-MeO-DMT is often described as difficult to put into language.
The experience can include profound emotional release, changes in body awareness, altered perception of time, dissolution of personal identity, feelings of unity, love or interconnectedness, and experiences people describe as spiritual or transcendent.
For others, grief, fear, pain or previously inaccessible emotion may emerge intensely.
And because visual imagery can be minimal, the experience may feel much less like "watching a psychedelic journey" and much more like being completely inside an emotional or existential experience.
That can be extraordinarily powerful.
Preparation and integration
A fifteen-minute psychedelic experience can still contain an enormous amount of emotional material.
The fact that 5-MeO-DMT is short does not necessarily mean the psychological process surrounding it is short.
People may spend days or weeks making sense of what happened, particularly after experiences involving major emotional release, grief, identity or profound shifts in perspective.
Preparation establishes trust and intention before the experience. Integration allows what emerged to become part of real life afterwards.
Remember: the medicine may open the door, but the work afterwards helps create lasting change.
Risks and considerations
06Medication and safety
In clinical trials, the most common physical effects were nausea, vomiting, headache, nasal discomfort and short-lived rises in blood pressure. [4, 7, 11]
Combining 5-MeO-DMT with MAOIs, which include some antidepressants and the vine used in ayahuasca, is dangerous. Tell anyone supporting you about every medication, supplement and substance you take, and never stop or change a prescribed medication without talking to your doctor. [17]
Many people report reactivations, brief moments when part of the experience returns in the days or weeks afterwards. Most describe these as neutral or positive, but they can be unsettling if you don't know they might happen. [18, 19]
Screening matters. Psychedelic treatments aren't suitable for everyone. People with a personal or family history of psychosis or bipolar disorder, some heart conditions, or who take certain medications may face serious risks.
Creating space afterwards
Because 5-MeO-DMT can produce such an intense shift followed by a relatively rapid return to normal awareness, the period afterwards deserves attention.
People can emerge feeling extraordinarily open, connected, peaceful or emotionally released. For some, that can also mean feeling unusually sensitive or expansive.
For anyone with a history of compulsive or addictive behaviour, having a supportive environment afterwards can be valuable, not because research currently shows 5-MeO-DMT causes addiction, but because major emotional states can influence how we behave once we return to ordinary life.
Interestingly, current evidence suggests relatively low craving for 5-MeO-DMT itself, and the medicine is now being researched as a potential treatment for alcohol-use disorder.
Access in Australia
5-MeO-DMT does not currently have the therapeutic prescribing pathway in Australia that exists for MDMA for PTSD or psilocybin for treatment-resistant depression.
Its development remains predominantly within research and clinical-trial environments.
Australia has already demonstrated a willingness to reconsider psychedelic medicines when sufficient evidence develops. With 5-MeO-DMT now moving into late-stage international clinical development, it will be an important medicine to watch.
- The experience can be sudden and overwhelming, including loss of physical control, which makes unsupervised use especially dangerous.
Questions to ask a practitioner
075-MeO-DMT can take hold within seconds, and once it begins there is no easing in. That makes everything agreed beforehand especially important, so ask as many questions as you need.
- Legal pathway: Is there any legal pathway to this treatment in Australia? If this is overseas or part of research, is it legal where it is offered, and is the trial registered?
- Qualifications and experience: Who is medically responsible during the session? What training and experience does the team have with 5-MeO-DMT specifically?
- Screening and suitability: What medical and psychological screening is included? How do you assess a personal or family history of psychosis or bipolar disorder, heart conditions and blood pressure? Which medications and substances do you check for, including antidepressants, MAOIs, ayahuasca and Syrian Rue?
- The medicine: Is the 5-MeO-DMT synthetic or toad-derived? How do you know what it contains and exactly how much I am receiving?
- Dosing: How do you decide on a dose? Can we begin with a lower one? Do you ever give more than one dose in a session, and how is that decided?
- Consent: Because I may not be able to speak once the effects begin, how do we agree beforehand on what support or touch is okay? Can I change my mind at any point before dosing?
- Preparation: How many preparation sessions are included, and how will you help me prepare for an experience this fast and intense?
- During the session: Who stays beside me the whole time? How do you keep me physically safe if I lose awareness of my body?
- Emergency procedures: What happens if I become overwhelmed, my blood pressure rises or I become medically unwell? What equipment and trained staff are on site, and what is your arrangement for getting me to a hospital if needed?
- Afterwards: Will you explain reactivations, where effects can briefly return days or weeks later, and who I can contact if they happen? When is it safe to go home, and should someone be with me for the rest of the day?
- Integration and ongoing support: How many follow-up sessions are included? Do you offer somatic or body-based approaches? What support is available if I struggle with what came up?
- Evidence and alternatives: What evidence supports your approach? What evidence-based treatments are available to me now?
The right practitioner will welcome every one of these questions. If someone rushes you or brushes them aside, that tells you something important.
Founder’s Insight
5-MeO-DMT has probably been one of the most profound experiences of my life, and it is something I will personally choose to revisit potentially for the rest of my life.
I don't get the visuals people often talk about. For me, it is much more emotional and physical. It has given me an incredible outlet for grief, pain and emotion, and at times it has felt as though things I had carried for years, even patterns and pain that felt bigger than my own lifetime, finally had somewhere to move. The best way I can describe it is like compressing years of therapy, emotional release and relief from grief into a single two to three-hour experience.
The closest way I can describe what comes afterwards is clearing the cache of my brain. The noise goes quiet and I can suddenly see how many of the patterns we live inside are not fixed. That has given me a very real sense that our behaviours, beliefs and even the way we live our lives can be rewired.
I have also learnt that dosing matters enormously. Smaller doses have sometimes allowed me to stay more connected to what is happening and lean into the emotion, rather than simply being overtaken by the intensity of it.
One of my most powerful experiences was layered with MDMA. There can be real fear and resistance before a psychedelic experience, especially with something as intense as 5-MeO-DMT, and the MDMA helped me soften into it. That journey brought up repressed memories from my childhood. I am incredibly grateful they surfaced, but even more grateful that I had strong therapeutic support around me to unpack them afterwards.
That is something I feel very strongly about. Assisted therapy should be part of these experiences. What opens up in a medicine journey can continue unfolding for weeks, even years depending on what you have repressed and having the right support around you, ideally someone who also understands somatic work, can make an enormous difference and should be essential.
I am also mindful of the hours afterwards. I can feel exceptionally open, good and emotionally released, and because addiction has been part of my own story, I know I need to be conscious of my environment and behaviours after a session. For me, it is about respecting how vulnerable and open you can feel after something this powerful.
I hope there comes a time when Australians can access 5-MeO-DMT in thoughtful, supported therapeutic settings. Personally, it has been one of the most extraordinary tools I have encountered.
You’ve read about it. Now what can you actually do?
You don’t need to have the perfect plan. Choose the next step that feels most useful for where you are right now.
Always speak with a qualified health professional before starting something new. If you are struggling right now, find immediate support.
Want to keep exploring?
Recommended articles, books, podcasts and lived experiences related to this topic.
Explore the LibraryRelated Tools
This is educational information. It is not a recommendation that this approach is right for you. Always speak with a qualified health professional.
